Newer Antiepileptic Drugs

Vimpat(lacosamide) is marketed by UCB Pharma. It is one of the newer AEDs on the market. It was approved by the FDA as an add-on medication for simple partial and complex partial seizures. Its precise mechanism of action is not known. It is not metabolized in the liver by the cytochrome P450 system and therefore lacks drug-drug interaction. Vimpat is available in tablet form and solution for daily use. When needed, it can be given intravenously. Its role is as a safe, effective antiepileptic drug which can be added on relatively fast to other AEDs without concern of drug interactions.

Banzel(rufinamide), manufactured by Eisai, is also a relatively new drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Banzel is metabolized in the liver (not by the cytochrome P450 system) and has interactions with other medications. Also, oral contraception will be rendered less effective, and the addition of non-hormonal forms of contraception is recommended when Banzel is used.

Onfi(clobazam), a relatively long-acting benzodiazepine, has been available in Europe since 1975. It was first approved as an anti-anxiety drug, and then in 1984 as an anti-seizure medication. In October of 2011, it was approved in the United States for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older. The dose depends on the patient’s weight and it is usually given two times per day. Onfi has significant drug interactions. Therefore it is important that the physician knows all medications a patient is taking. Patients are not to drink alcohol while using Onfi. Before Onfi can be started, the physician will need to obtain prior approval from most insurance companies

This site is presented for information only and is not intended to substitute for professional medical advice. Use of this site is subject to a disclaimer. Presentation and design ©Copyright 2000 Rev. 2005 MINCEP® Epilepsy Care.
All Rights Reserved.